Product Catalog [{"id":"632","name":"Voranigo (vorasidenib) ","price":30508.27,"sku":"Voranigo (vorasidenib)","brand":"Servier ","position":1,"category":"Medicines\/Oncology\/Head and Neck Cancer"},{"id":"580","name":"Loqtorzi","price":14739.3,"sku":"Loqtorzi (toripalimab-tpzi)","brand":false,"position":2,"category":"Medicines\/Oncology\/Head and Neck Cancer"},{"id":"35","name":"Keytruda","price":4225.5,"sku":"Keytruda (pembrolizumab)","brand":"Merck Sharp ","position":3,"category":"Medicines\/Oncology\/Head and Neck Cancer"},{"id":"21","name":"Opdivo","price":867.24,"sku":"Opdivo (nivolumab)","brand":"Bristol-Myers Squibb Pharma EEIG","position":4,"category":"Medicines\/Oncology\/Head and Neck Cancer"}]

Head and Neck Cancer access options

Head and neck cancers are a group of cancers that form in the tissues of the upper aerodigestive tract (lips, tongue, mouth, throat and larynx or voice box) or the sinuses and nasal cavity. Most head and neck cancers originate from the squamous cells that make up the lining of these tracts and cavities and are therefore called squamous cell carcinomas. Head and neck cancers represent 4% of all cancers worldwide, with more than 550,000 new cases each year. The location most frequently affected is the oral cavity, counting for 41% of all head and neck cancers, followed by pharynx and larynx cancers with 22% and 24% respectively.
  1. Opdivo
    Opdivo (Nivolumab)
    Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer
    €867.24
  2. Keytruda
    Keytruda (pembrolizumab)
    Urothelial Carcinoma, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Skin Cancer
    €4,225.50
  3. Loqtorzi
    Loqtorzi (toripalimab-tpzi)
    Head and Neck Cancer
    €14,739.30
  4. Voranigo (vorasidenib)
    Voranigo (vorasidenib) (vorasidenib)
    Head and Neck Cancer
    €30,508.27
View as Grid List

4 Items

Set Descending Direction
Read more about the latest treatments in Head and Neck Cancer
US 0